Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akoya Biosciences (AKYA)
NASDAQ:AKYA
AKYA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.88 - $6.31
Previous CloseN/A
Volume11.73K
Average Volume (3M)1.10M
Market Cap
$102.12M
Enterprise Value$183.67M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.71
Next Earnings
Mar 10, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding49,572,746
10 Day Avg. Volume415,154
30 Day Avg. Volume1,098,948
Standard Deviation0.17
R-Squared0.12
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.18
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.26
Enterprise Value/Ebitda-4.62
Forecast
1Y Price Target
$3.50Price Target Upside70.73% Upside
Rating ConsensusHold
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Market ExpansionQTRX will add a new ~$5B SAM in oncology/immunology and can leverage AKYA's tissue-based protein biomarkers for a planned, integrated solution to identify biomarkers across both tissue and blood samples.
Merger And AcquisitionShares of AKYA gained 14% following the news that it reached a definitive agreement to be acquired by Quanterix in an all-stock transaction.
Strategic ManagementAKYA's CEO, Brian McKelligon, plans to join the combined company, which is viewed positively given his expertise with AKYA's products and knowledge in oncology.
Bears Say
Financial PerformanceAKYA announced on its Q3 call that it was pursuing strategic alternatives after its third consecutive miss and guide down.
Revenue GuidanceAkoya has significantly lowered its 2024 revenue guidance and no longer believes it will achieve cash flow breakeven in 4Q24.
Sales And Funding ChallengesThe primary driver of the 3Q24 miss was lack of funding among Akoya's customer base, which has pressured sales of capital equipment in the life science tools sector.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
AKYA FAQ
What was Akoya Biosciences’s price range in the past 12 months?
Akoya Biosciences lowest stock price was $1.88 and its highest was $6.31 in the past 12 months.
What is Akoya Biosciences’s market cap?
Akoya Biosciences’s market cap is $102.12M.
When is Akoya Biosciences’s upcoming earnings report date?
Akoya Biosciences’s upcoming earnings report date is Mar 10, 2025 which is in 15 days.
How were Akoya Biosciences’s earnings last quarter?
Akoya Biosciences released its earnings results on Nov 14, 2024. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.2 by -$0.01.
Is Akoya Biosciences overvalued?
According to Wall Street analysts Akoya Biosciences’s price is currently Undervalued.
Does Akoya Biosciences pay dividends?
Akoya Biosciences does not currently pay dividends.
What is Akoya Biosciences’s EPS estimate?
Akoya Biosciences’s EPS estimate is -0.16.
How many shares outstanding does Akoya Biosciences have?
Akoya Biosciences has 49,572,746 shares outstanding.
What happened to Akoya Biosciences’s price movement after its last earnings report?
Akoya Biosciences reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.2. Following the earnings report the stock price went down -23.003%.
Which hedge fund is a major shareholder of Akoya Biosciences?
Currently, no hedge funds are holding shares in AKYA
---
Akoya Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.50 (70.73% Upside)
$3.50 (70.73% Upside)
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-63.41%
12-Months-Change
Fundamentals
Return on Equity
-153.34%
Trailing 12-Months
Asset Growth
-26.67%
Trailing 12-Months
Company Description
Akoya Biosciences
Akoya Biosciences Inc is an an innovative life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery and clinical research. It offers the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications.
---
AKYA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a challenging quarter for Akoya Biosciences, with significant revenue declines and underperformance in instrument sales due to market constraints. However, improvements in operational efficiencies and strategic advancements in the clinical pipeline provide a positive outlook for long-term growth.Read More>---
AKYA Stock 12 Month Forecast
Average Price Target
$3.50
▲(70.73% Upside)
Technical Analysis
Best Analysts Covering AKYA
1 Year
1 Year Success Rate
1/16 ratings generated profit
1 Year Average Return
-35.12%
assigned a buy rating 3 months ago
Copying David Westenberg's trades and holding each position for 1 Year would result in 6.25% of your transactions generating a profit, with an average return of -35.12% per trade.
---